Trial Profile
A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy and Safety Study of SYMBICORT pMDI 2 x 160/4.5 microg and 80/4.5 microg Bid Compared to Formoterol TBH, Budesonide pMDI (and the Combination) and Placebo in COPD Patients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Budesonide/formoterol (Primary) ; Budesonide; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms SHINE
- Sponsors AstraZeneca
- 18 May 2011 Results presented at the 107th International Conference of the American Thoracic Society.
- 20 May 2009 Symptom exacerbation results reported at the 105th International Conference of the American Thoracic Society.
- 20 May 2009 Results on symptoms reported at the 105th International Conference of the American Thoracic Society.